Leforate 20 Tablet contains Leflunomide 20 mg, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. Leflunomide exerts its therapeutic effect by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammation and joint damage. This immunomodulatory action helps to alleviate symptoms such as joint pain, swelling, and stiffness, and slows the progression of structural joint damage. Leforate 20 is administered orally, typically once daily, with or without food, and dosage adjustments may be necessary based on clinical response and tolerability. It is important to monitor liver function tests and complete blood counts regularly during therapy due to potential hepatotoxicity and hematologic adverse effects. Leflunomide is contraindicated in patients with severe hepatic impairment, pregnancy, or hypersensitivity to the drug. Patients should be advised about potential side effects including gastrointestinal disturbances, rash, alopecia, and increased susceptibility to infections. Leforate 20 should be used under strict medical supervision with appropriate monitoring to ensure safety and efficacy in managing autoimmune inflammatory conditions.